Anavex life sciences to present at the evercore isi 3rd annual healthconx conference

New york, nov. 25, 2020 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) diseases, today announced that its president & chief executive officer, christopher u. missling, phd, will present at the virtual evercore isi 3rd annual healthconx conference on thursday, december 3, 2020 at 11:45 a.m. et.
AVXL Ratings Summary
AVXL Quant Ranking